Search the Newsreel

PTC Therapeutics (NASDAQ:PTCT) Posts Quarterly Earnings Results, Beats Expectations By $0.68 EPS

PTC Therapeutics (PTCT) Beats Q2 Earnings and Revenue Estimates

PTC Therapeutics Number of Employees 2026 | Employee Count & Headcount Data

PTC Therapeutics (PTCT) had 988 employees worldwide as of March 2026, a 28.2% decline since 2023. The company is actively hiring, with 45 active job postings in 2026, and its workforce is primarily concentrated in the United States. The article also details employee distribution …

Renaissance Technologies LLC Sells 74,289 Shares of PTC Therapeutics, Inc. $PTCT

Renaissance Technologies LLC has reduced its stake in PTC Therapeutics, Inc. by 12.2%, selling 74,289 shares and now owning 533,300 shares valued at $36.33 million. Other institutional investors have also adjusted their positions in the biopharmaceutical company. PTC Therapeutics' stock opened at $75.39, with …

PTC Therapeutics, Inc. $PTCT Shares Bought by Rock Springs Capital Management LP

Rock Springs Capital Management LP significantly increased its stake in PTC Therapeutics (PTCT) by 161.5% in the first quarter, now holding 161,798 shares valued at $11 million. This comes as PTC Therapeutics reported strong Q1 revenue of $272.55 million, a 43.5% year-over-year increase, and …

PTC Therapeutics (PTCT) Receives a Hold from RBC Capital

RBC Capital analyst Brian Abrahams maintained a Hold rating on PTC Therapeutics (PTCT) and set a price target of $85.00. Despite a Strong Buy consensus among analysts with an average price target of $98.64, the company reported a GAAP net loss in its latest …

PTC Therapeutics, Inc. (PTCT) Stock Analysis: Evaluating a 26.74% Potential Upside Amidst Volatile Revenue Growth

PTCT|PTC Therapeutics Inc|Price:75.790|Chg%:-1.030

This article provides a comprehensive stock analysis of PTC Therapeutics Inc (PTCT) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Pharmaceuticals industry. The analysis also covers institutional confidence, analyst ratings, and the company's product portfolio, emphasizing …

Orbimed Advisors LLC Has $3.35 Million Stake in PTC Therapeutics, Inc. $PTCT

Orbimed Advisors LLC significantly increased its stake in PTC Therapeutics (NASDAQ:PTCT) by 111.6% in the first quarter, now holding 49,100 shares valued at approximately $3.35 million. This increase comes despite recent insider selling by two executives totaling $3.61 million and other insider sales amounting …

PTC Therapeutics Inc (PTCT) Balance Sheet

This article provides the quarterly and annual balance sheet data for PTC Therapeutics Inc (PTCT), allowing users to analyze its financial health, liquidity, leverage, and return on equity. It includes detailed financial figures for various assets, liabilities, and shareholders' equity categories spanning multiple years …

PTC Therapeutics' Phenylketonuria Physician Survey Yielded Mixed Results on Sephience Launch Momentum, RBC Says

RBC Capital Markets conducted a physician survey regarding PTC Therapeutics' drug Sephience for phenylketonuria (PKU). The survey results were mixed, indicating some positive feedback but also highlighting challenges in the drug's launch momentum. This suggests that while there's potential, the uptake of Sephience might …

PTC Therapeutics Inc (PTCT) Shareholder Structure: Major Shareholders & Institutional Holdings

The article details the shareholder structure of PTC Therapeutics Inc (PTCT), highlighting its major shareholders and institutional holdings. It provides a breakdown of significant institutional investors like BlackRock and RTW Investments, along with analysis of shareholder types and changes in institutional shareholding over recent …

PTC Therapeutics Inc (PTCT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article from TradingKey provides a dividend and stock split report for PTC Therapeutics Inc (PTCT). It states that the company has not distributed any dividends over the past five years. The page includes current stock information such as share price, market cap, and …

PTC Therapeutics Inc (PTCT) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for PTC Therapeutics Inc (PTCT), showing a current earnings forecast score of 7.50, ranking 101 out of 155 in the Pharmaceuticals industry. Analysts have set an average price target of $80.00, with a majority recommending a "Buy" for …

PTC Therapeutics, Inc. Revenue Breakdown – BOATS:PTCT

PTC Therapeutics, Inc. (PTCT) generated $1.73 billion in revenue last year, with its Life Science segment being the primary contributor, also at $1.73 billion. The United States was the leading geographical source of revenue, accounting for $1.49 billion. This data highlights the company's key …

PTCT5396017 Bond Profile — Key Metrics

This article provides a detailed profile of the PTCT5396017 bond issued by PTC Therapeutics, Inc. Key metrics include its 1.5% coupon rate, an issue date of April 8, 2022, and a maturity date of September 15, 2026. The biopharmaceutical company focuses on rare disorders …

Will PTC Therapeutics (PTCT) Report Negative Earnings Next Week? What You Should Know

PTC Therapeutics (PTCT) is expected to report a year-over-year increase in earnings on higher revenues for the quarter ended June 2026, despite a projected quarterly loss of $0.09 per share. The consensus EPS estimate has been revised 38.1% lower over the last 30 days. …

Barclays Maintains PTC Therapeutics(PTCT.US) With Buy Rating, Maintains Target Price $120

Barclays has reiterated its Buy rating for PTC Therapeutics (PTCT.US) and maintained its price target at $120. This indicates the firm's continued confidence in the company's financial prospects. Investors can use this information as part of their broader research into PTCT.US.

PTCT Maintained by Wells Fargo -- Price Target Lowered to $93.00

Wells Fargo maintained its "Overweight" rating for PTC Therapeutics (PTCT) but lowered its price target from $95.00 to $93.00. GuruFocus's GF Value™ indicates the stock is 115.4% overvalued, with a current price of $78.59 against a GF Value™ of $36.48. The company's GF Score™ …

Is PTC Therapeutics (PTCT) Cheap On Fast Track News For PTC518?

PTC Therapeutics, Inc. (PTCT) received Fast Track designation for its PTC518 Huntington's disease program, prompting a re-evaluation of the stock. While a discounted cash flow model suggests significant undervaluation with a fair value of $253.95, the price-to-sales ratio is only slightly below peers, indicating …

PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results, and provide a business update and outlook. Individuals can access the live webcast via …

PTC Therapeutics schedules second-quarter 2026 results webcast conference call

PTC Therapeutics is scheduled to report its second-quarter 2026 financial results on July 30, 2026. A webcast conference call will be held on the same day at 4:30 p.m. ET, with a replay available for 30 days. This news brief was generated by Public …

Form 4 PTC Therapeutics Inc For: 16 July By Investing.com

This article from Investing.com reports that a Form 4 filing for PTC Therapeutics Inc. was made on July 16, 2026. Form 4s disclose transactions by company insiders, but the article does not provide specific details about the transactions. The content primarily consists of market …

PTC Therapeutics (PTCT) CFO auto-sells 3,494 shares to cover RSU taxes

PTC Therapeutics' CFO, Pierre Gravier, automatically sold 3,494 shares of common stock at $80.35 per share on July 14, 2026. This transaction was executed to fulfill tax withholding obligations tied to the vesting of 6,500 RSUs. After this sale, Gravier directly holds 83,986 shares …

PTC Therapeutics Sets July 30 Webcast for Business Update

PTC Therapeutics (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, July 30, 2026, at 4:30 p.m. ET to report its second quarter 2026 financial results and provide a business and outlook update. Investors can access the live webcast and replay …

PTC Therapeutics (PTCT) Gets a Buy from Bank of America Securities

Bank of America Securities analyst Tazeen Ahmad reiterated a Buy rating on PTC Therapeutics (PTCT) with a $95.00 price target. This follows a similar Buy rating from J.P. Morgan, though RBC Capital maintained a Hold rating. The company recently reported a quarterly revenue of …

What PTC Therapeutics (PTCT)'s Q1 Beat and Sephience Outlook Shift Mean For Shareholders

PTC Therapeutics reported strong Q1 2026 earnings, surpassing analyst expectations, and a positive outlook for its rare disease therapy, Sephience. This has led to renewed optimism and analyst upgrades, despite pre-planned insider stock sales. The company's future investment narrative hinges on Sephience offsetting concentration …

Cantor Fitzgerald reiterates Overweight on PTC Therapeutics stock

Cantor Fitzgerald has reiterated an Overweight rating and a $124 price target for PTC Therapeutics (NASDAQ:PTCT), citing a strong launch for its PKU treatment, Sephience. The firm plans to engage management to discuss Sephience's global expansion, potential FDA dialogue for votoplaln in Huntington's disease, …